Upcoming Earnings Report: Analyzing Recent Insider Trading and Hedge Fund Activity for $HOLX

HOLOGIC, trading under the ticker symbol $HOLX, is gearing up to unveil its latest quarterly earnings data on Monday, November 3rd after the markets close, as reported by Finnhub. Market analysts have pegged revenue expectations at $1,054,697,421, with anticipated earnings per share set at $1.12. For a comprehensive overview of various metrics concerning HOLOGIC, enthusiasts can access Quiver Quantitative’s dedicated $HOLX stock page, which provides valuable insights into insider trading trends, hedge fund maneuvers, congressional moves, and more.

In terms of insider trading activity within HOLOGIC, a snippet of intriguing data emerges. Over the past half-year, HOLOGIC insiders have engaged in five stock transactions on the open market, with one being a purchase and the remaining four constituting sales. Noteworthy transactions include Chairman, President, and CEO, Stephen P MacMillan, who executed three sales, offloading 138,358 shares amounting to an estimated $9,266,117. Likewise, Christiana Stamoulis divested 7,402 shares valued at $540,864, while Martin D Madaus acquired 5,445 shares estimated at $300,760.

Transitioning to hedge fund activity surrounding HOLOGIC, staggering figures have surfaced. 330 institutional investors opted to amplify their HOLOGIC stock holdings in the most recent quarter, while 375 decided to scale back their positions. Key highlights from the past quarter encompass sizeable adjustments in stock ownership by prominent players such as The Manufacturers Life Insurance Company, Morgan Stanley, T. Rowe Price Investment Management, Inc., Mitsubishi UFJ Asset Management Co., Ltd., Invesco Ltd., Citadel Advisors LLC, and Macquarie Group Ltd.

Furthermore, award payments totaling $22,547,364 were allocated to HOLOGIC over the last twelve months through assorted government contracts. Notable disbursements in this domain encapsulate contracts for annual maintenance, XR mammography equipment, reagent rentals, Aptima SARS-CoV-2/flu assay supplies, and other pertinent healthcare contributions.

Analyst assessments of HOLOGIC have not gone unnoticed, with 1 firm issuing a buy rating for the stock in recent months. This favorable nod was extended by Citigroup on 07/09/2025, reinforcing confidence in HOLOGIC’s future trajectory. Moreover, a spate of price targets set by multiple analysts have been disclosed recently, with a median target of $78.0 established based on recommendations by industry experts from Mizuho, JP Morgan, Stephens & Co., Leerink Partners, Evercore ISI Group, Argus Research, and RBC Capital among others.

For a comprehensive breakdown of all matters related to HOLOGIC, from insider trading behaviors and hedge fund activities to government contracts and analyst evaluations, interested individuals can peruse Quiver Quantitative’s designated platforms for detailed insights and real-time data updates. Remember, the information shared in this article is for informational purposes and does not constitute financial advice; discrepancies may occur due to ticker mapping errors and other anomalies.